Home › Gilead Announces Results from Phase 2 Study Showing Reduction in...
 

Keywords :   


Gilead Announces Results from Phase 2 Study Showing Reduction in...

2014-05-11 00:54:46| Biotech - Topix.net

Gilead Sciences, Inc. today announced results from HARMONY, a randomized, double-blind, placebo-controlled Phase 2 study evaluating the effect of ranolazine and low-dose dronedarone, each given alone and in combination, on atrial fibrillation burden in patients with paroxysmal atrial fibrillation .

Tags: in results showing study

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
29.06Eastern North Pacific Tropical Weather Outlook
29.06Atlantic Tropical Weather Outlook
29.06Tropical Storm Beryl Graphics
29.06Tropical Storm Beryl Forecast Discussion Number 2
29.06Tropical Storm Beryl Public Advisory Number 2
29.06Summary for Tropical Storm Beryl (AT2/AL022024)
29.06Tropical Storm Beryl Wind Speed Probabilities Number 2
29.06Tropical Storm Beryl Forecast Advisory Number 2
More »